[1] World Health Organization, Cancer, Web Page. (n.d.). https://www.who.int/health-topics/cancer#tab=tab_1 (accessed January 6, 2021).
[2] World Health Organization, Globocan 2020:Lip, oral cavity. International Agency for Research on Cancer, Web Page. (2020). https://gco.iarc.fr/today/data/factsheets/cancers/1-Lip-oral-cavity-fact-sheet.pdf (accessed January 6, 2021).
[3] T.M. Pimenta Amaral, A.R. Da Silva Freire, A.L. Carvalho, C.A.L. Pinto, L.P. Kowalski, Predictive factors of occult metastasis and prognosis of clinical stages I and II squamous cell carcinoma of the tongue and floor of the mouth, Oral Oncol. 40 (2004) 780–786. https://doi.org/10.1016/j.oraloncology.2003.10.009.
[4] T. Sasahira, T. Kirita, Hallmarks of cancer-related newly prognostic factors of oral squamous cell carcinoma, Int. J. Mol. Sci. 19 (2018). https://doi.org/10.3390/ijms19082413.
[5] G. La Rocca, I. Pucci-Minafra, A. Marrazzo, P. Taormina, S. Minafra, Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera, Br. J. Cancer. 90 (2004) 1414–1421. https://doi.org/10.1038/sj.bjc.6601725.
[6] R.D. Singh, • N Haridas, • Jayendra, B. Patel, F.D. Shah, S.N. Shukla, • Pankaj, M. Shah, • Prabhudas, S. Patel, Matrix Metalloproteinases and Their Inhibitors: Correlation with Invasion and Metastasis in Oral Cancer, (n.d.). https://doi.org/10.1007/s12291-010-0060-8.
[7] A. Staack, S. Badendieck, D. Schnorr, S.A. Loening, K. Jung, Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder, BMC Urol. 6 (2006) 1–12. https://doi.org/10.1186/1471-2490-6-19.
[8] J. Decock, S. Thirkettle, L. Wagstaff, D.R. Edwards, Matrix metalloproteinases: Protective roles in cancer, J. Cell. Mol. Med. 15 (2011) 1254–1265. https://doi.org/10.1111/j.1582-4934.2011.01302.x.
[9] T. Turpeenniemi-Hujanen, Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers, Biochimie. 87 (2005) 287–297. https://doi.org/10.1016/j.biochi.2005.01.014.
[10] PDQ Adult Treatment Editorial Board, Lip and Oral Cavity Cancer Treatment (Adult) (PDQ®): Patient Version, 2002. http://www.ncbi.nlm.nih.gov/pubmed/26389326 (accessed January 6, 2021).
[11] G. Calixto, J. Bernegossi, B. Fonseca-Santos, M. Chorilli, Nanotechnology-based drug delivery systems for treatment of oral cancer: A review, Int. J. Nanomedicine. 9 (2014) 3719–3735. https://doi.org/10.2147/IJN.S61670.
[12] S.H. Huang, B. O’Sullivan, Oral cancer: Current role of radiotherapy and chemotherapy, Med. Oral Patol. Oral Cir. Bucal. 18 (2013). https://doi.org/10.4317/medoral.18772.
[13] D.J. Newman, G.M. Cragg, Natural Products as Sources of New Drugs from 1981 to 2014, J. Nat. Prod. 79 (2016) 629–661. https://doi.org/10.1021/acs.jnatprod.5b01055.
[14] S.C. Thomasset, D.P. Berry, G. Garcea, T. Marczylo, W.P. Steward, A.J. Gescher, Dietary polyphenolic phytochemicals - Promising cancer chemopreventive agents in humans? A review of their clinical properties, Int. J. Cancer. 120 (2007) 451–458. https://doi.org/10.1002/ijc.22419.
[15] J.N. Losso, R.R. Bansode, A. Trappey, H.A. Bawadi, R. Truax, In vitro anti-proliferative activities of ellagic acid, J. Nutr. Biochem. 15 (2004) 672–678. https://doi.org/10.1016/j.jnutbio.2004.06.004.
[16] C. Girish, S.C. Pradhan, Drug development for liver diseases: Focus on picroliv, ellagic acid and curcumin, Fundam. Clin. Pharmacol. 22 (2008) 623–632. https://doi.org/10.1111/j.1472-8206.2008.00618.x.
[17] N. Wang, Z.Y. Wang, S.L. Mo, T.Y. Loo, D.M. Wang, H. Bin Luo, D.P. Yang, Y.L. Chen, J.G. Shen, J.P. Chen, Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer, Breast Cancer Res. Treat. 134 (2012) 943–955. https://doi.org/10.1007/s10549-012-1977-9.
[18] D.H. Han, M.J. Lee, J. Kim, Antioxidant and apoptosis-inducing activities of ellagic acid., Undefined. (2006).
[19] M. Edderkaoui, A. Lugea, H. Hui, G. Eibl, Q.Y. Lu, A. Moro, X. Lu, G. Li, V.L. Go, S.J. Pandol, Ellagic acid and embelin affect key cellular components of pancreatic adenocarcinoma, cancer, and stellate cells, Nutr. Cancer. 65 (2013) 1232–1244. https://doi.org/10.1080/01635581.2013.832779.
[20] M. Edderkaoui, I. Odinokova, I. Ohno, I. Gukovsky, V.L.W. Go, S.J. Pandol, A.S. Gukovskaya, Ellagic acid induces apoptosis through inhibition of nuclear factor κB in pancreatic cancer cells, World J. Gastroenterol. 14 (2008) 3672–3680. https://doi.org/10.3748/wjg.14.3672.
[21] S.T. Huang, C.Y. Wang, R.C. Yang, C.J. Chu, H.T. Wu, J.H.S. Pang, Phyllanthus urinaria increases apoptosis and reduces telomerase activity in human nasopharyngeal carcinoma cells., Forsch. Komplementmed. 16 (2009) 34–40. https://doi.org/10.1159/000194154.
[22] J. Bagan, G. Sarrion, Y. Jimenez, Oral cancer: Clinical features, Oral Oncol. 46 (2010) 414–417. https://doi.org/10.1016/j.oraloncology.2010.03.009.
[23] E. Attar, S. Dey, A. Hablas, I.A. Seifeldin, M. Ramadan, L.S. Rozek, A.S. Soliman, Head and neck cancer in a developing country: A population-based perspective across 8 years, Oral Oncol. 46 (2010) 591–596. https://doi.org/10.1016/j.oraloncology.2010.05.002.
[24] S. Petti, Lifestyle risk factors for oral cancer, Oral Oncol. 45 (2009) 340–350. https://doi.org/10.1016/j.oraloncology.2008.05.018.
[25] J.P. Shah, Z. Gil, Current concepts in management of oral cancer - Surgery, Oral Oncol. 45 (2009) 394–401. https://doi.org/10.1016/j.oraloncology.2008.05.017.
[26] P. Sugerman, N. Savage, Oral Cancer in Australia: 1983–1996, Aust. Dent. J. 47 (2002) 45–56. https://doi.org/10.1111/j.1834-7819.2002.tb00303.x.
[27] P.M. Main JH, Actinic cheilitis and carcinoma of the lip, J Can Dent Assoc. 60 (1994) 113–6.
[28] A.M. Alves, M.B. Correa, K. Duarte Da Silva, L.M. Aver De Araújo, A. Carolina, U. Vasconcelos, A. Paula, N. Gomes, A. Etges, S.B. Chaves Tarquinio, Demographic and Clinical Profile of Oral Squamous Cell Carcinoma from a Service-Based Population, Braz. Dent. J. 28 (2017) 301–306. https://doi.org/10.1590/0103-6440201601257.
[29] K. Dhanuthai, S. Rojanawatsirivej, W. Thosaporn, S. Kintarak, A. Subarnbhesaj, M. Darling, E. Kryshtalskyj, C.P. Chiang, H.I. Shin, S.Y. Choi, S.S. Lee, P.A. Shakib, Oral cancer: A multicenter study, Med. Oral Patol. Oral y Cir. Bucal. 23 (2018) e23–e29. https://doi.org/10.4317/medoral.21999.
[30] D. Brandizzi, M. Gandolfo, M.L. Velazco, R.L. Cabrini, H.E. Lanfranchi, Clinical features and evolution of oral cancer: A study of 274 cases in Buenos Aires, Argentina, n.d. http://www.medicinaoral.com/medoralfree01/v13i9/medoralv13i9p544.pdf (accessed January 21, 2021).
[31] Y. Ariyoshi, M. Shimahara, K. Omura, E. Yamamoto, H. Mizuki, H. Chiba, Y. Imai, S. Fujita, M. Shinohara, K. Seto, Epidemiological study of malignant tumors in the oral and maxillofacial region: Survey of member institutions of the Japanese Society of Oral and Maxillofacial Surgeons, 2002, Int. J. Clin. Oncol. 13 (2008) 220–228. https://doi.org/10.1007/s10147-007-0756-9.
[32] K. Sargeran, H. Murtomaa, S.M.R. Safavi, M. Vehkalahti, O. Teronen, Malignant oral tumors in Iran: Ten-year analysis on patient and tumor characteristics of 1042 patients in Tehran, J. Craniofac. Surg. 17 (2006) 1230–1233. https://doi.org/10.1097/01.scs.0000246728.23483.ce.
[33] J. Da, S. Moro, M. Cunha Maroneze, T. Machado Ardenghi, L. Machado Barin, C.C. Danesi, Oral and oropharyngeal cancer: epidemiology and survival analysis Câncer de boca e orofaringe: epidemiologia e análise da sobrevida ❚ ABSTRACT, 16 (2018) 1–5. https://doi.org/10.1590/S1679-45082018AO4248.
[34] J.B. Epstein, M. Gorsky, R.J. Cabay, T. Day, W. Gonsalves, Screening for and diagnosis of oral premalignant lesions and oropharyngeal squamous cell carcinoma: Role of primary care physicians, Can. Fam. Physician. 54 (2008) 870–875. /pmc/articles/PMC2426981/?report=abstract (accessed January 21, 2021).
[35] J. Massano, F.S. Regateiro, G. Januário, A. Ferreira, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, (2006). https://doi.org/10.1016/j.tripleo.2005.07.038.
[36] M. Becker, Oral cavity, oropharynx, and hypopharynx, Semin. Roentgenol. 35 (2000) 21–30. https://doi.org/10.1016/S0037-198X(00)80029-2.
[37] D.W.T. Vogel, T. Vogel, P. Zbaeren, H.C. Thoeny, Cancer of the oral cavity and oropharynx, Cancer Imaging. 10 (2010) 62–72. https://doi.org/10.1102/1470-7330.2010.0008.
[38] S. Ramasamy, N. Abdul Wahab, N. Zainal Abidin, S. Manickam, Z. Zakaria, Growth Inhibition of Human Gynecologic and Colon Cancer Cells by Phyllanthus watsonii through Apoptosis Induction, PLoS One. 7 (2012) e34793. https://doi.org/10.1371/journal.pone.0034793.
[39] G.M. Cragg, D.J. Newman, Plants as a source of anti-cancer agents, J. Ethnopharmacol. 100 (2005) 72–79. https://doi.org/10.1016/j.jep.2005.05.011.
[40] L. Vanella, C. Di Giacomo, R. Acquaviva, I. Barbagallo, V. Cardile, D.H. Kim, N.G. Abraham, V. Sorrenti, Apoptotic markers in a prostate cancer cell line: Effect of ellagic acid, Oncol. Rep. 30 (2013) 2804–2810. https://doi.org/10.3892/or.2013.2757.
[41] Y. Ding, H. Yao, Y. Yao, L.Y. Fai, Z. Zhang, Protection of dietary polyphenols against oral cancer, Nutrients. 5 (2013) 2173–2191. https://doi.org/10.3390/nu5062173.
[42] H.M. Zhang, L. Zhao, H. Li, H. Xu, W.W. Chen, L. Tao, Research progress on the anticarcinogenic actions and mechanisms of ellagic acid, Cancer Biol. Med. 11 (2014) 92–100. https://doi.org/10.7497/j.issn.2095-3941.2014.02.004.
[43] Y.-C. Hseu, C.-W. Chou, K.J. Senthil Kumar, K.-T. Fu, H.-M. Wang, L.-S. Hsu, Y.-H. Kuo, C.-R. Wu, S.-C. Chen, H.-L. Yang, Ellagic acid protects human keratinocyte (HaCaT) cells against UVA-induced oxidative stress and apoptosis through the upregulation of the HO-1 and Nrf-2 antioxidant genes, (2012). https://doi.org/10.1016/j.fct.2012.02.020.
[44] B. Krampe, M. Al-Rubeai, Cell death in mammalian cell culture: Molecular mechanisms and cell line engineering strategies, Cytotechnology. 62 (2010) 175–188. https://doi.org/10.1007/s10616-010-9274-0.
[45] B.F. Matte, A. Kumar, J.K. Placone, V.G. Zanella, M.D. Martins, A.J. Engler, M.L. Lamers, Matrix stiffness mechanically conditions EMT and migratory behavior of oral squamous cell carcinoma, J. Cell Sci. 132 (2019). https://doi.org/10.1242/jcs.224360.
[46] W. Jh, A.G. Schuck, R. Se, W. Bj, F. Sr, Z. Hl, Babich H, Ácido elágico é citotóxico seletivo na carcinoma oral tipo HSC-2 Ellagic Acid, a Dietary Polyphenol, Selectively Cytotoxic to HSC-2 Oral Carcinoma Cells. Author information, 2013.
[47] M. Zhao, S.N. Tang, J.L. Marsh, S. Shankar, R.K. Srivastava, Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice, Cancer Lett. 337 (2013) 210–217. https://doi.org/10.1016/j.canlet.2013.05.009.
[48] Y.-C. Chung, L.-C. Lu, M.-H. Tsai, Y.-J. Chen, Y.-Y. Chen, S.-P. Yao, C.-P. Hsu, The Inhibitory Effect of Ellagic Acid on Cell Growth of Ovarian Carcinoma Cells, Evidence-Based Complement. Altern. Med. 2013 (2013). https://doi.org/10.1155/2013/306705.
[49] Y. Xu, W. Wang, J. Huang, W. Zhu, Ellagic acid induces esophageal squamous cell carcinoma cell apoptosis by modulating <scp>SHP</scp> ‐1/ <scp>STAT3</scp> signaling, Kaohsiung J. Med. Sci. 36 (2020) 699–704. https://doi.org/10.1002/kjm2.12224.
[50] M.D. Sternlicht, P. Kedeshian, Z.M. Shao, S. Safarians, S.H. Barsky, The human myoepithelial cell is a natural tumor suppressor., Clin. Cancer Res. 3 (1997).
[51] C. Gialeli, A.D. Theocharis, N.K. Karamanos, Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting, FEBS J. 278 (2011) 16–27. https://doi.org/10.1111/j.1742-4658.2010.07919.x.
[52] L. Nakopoulou, S. Katsarou, I. Giannopoulou, P. Alexandrou, I. Tsirmpa, E. Panayotopoulou, J. Mavrommatis, A. Keramopoulos, Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients’ survival in breast cancer, Mod. Pathol. 15 (2002) 26–34. https://doi.org/10.1038/modpathol.3880486.
[53] S.A.E. P O-Charoenrat, P H Rhys-Evans, Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck, Arch Otolaryngol Head Neck Surg. Jul; 127 (2001) 813–20.
[54] R.D. Singh, N. Haridas, J.B. Patel, F.D. Shah, S.N. Shukla, P.M. Shah, P.S. Patel, Matrix metalloproteinases and their inhibitors: Correlation with invasion and metastasis in oral cancer, Indian J. Clin. Biochem. 25 (2010) 250–259. https://doi.org/10.1007/s12291-010-0060-8.
[55] S.-T. Huang, R.-C. Yang, H.-T. Wu, C.-N. Wang, J.-H.S. Pang, Zinc-Chelation Contributes to the Anti-Angiogenic Effect of Ellagic Acid on Inhibiting MMP-2 Activity, Cell Migration and Tube Formation, PLoS One. 6 (2011) e18986. https://doi.org/10.1371/journal.pone.0018986.
[56] N. Devipriya, A.R. Sudheer, M. Srinivasan, V.P. Menon, Effect of ellagic acid, a plant polyphenol, on fibrotic markers (MMPs and TIMPs) during alcohol-induced hepatotoxicity, Toxicol. Mech. Methods. 17 (2007) 349–356. https://doi.org/10.1080/15376510601077003.
[57] D.A. Vattem, K. Shetty, Biological functionality of ellagic acid: A review, J. Food Biochem. 29 (2005) 234–266. https://doi.org/10.1111/j.1745-4514.2005.00031.x.
[58] R.W. Teel, M.S. Babcock, R. Dixit, G.D. Stoner, Ellagic acid toxicity and interaction with benzo[a]pyrene and benzo[a]pyrene 7,8-dihydrodiol in human bronchial epithelial cells, Cell Biol. Toxicol. 2 (1986) 53–62. https://doi.org/10.1007/BF00117707.
[59] D.E. Gomez, D.F. Alonso, H. Yoshiji, U.P. Thorgeirsson, Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions, Eur. J. Cell Biol. 74 (1997) 111–122. https://europepmc.org/article/med/9352216 (accessed January 30, 2021).
[60] G. Kendre, R. Raghavan, S. Cheriyamundath, J. Madassery, Tetracycline and Glutathione Inhibit Matrix Metalloproteinase Activity: An In Vitro Study Using Culture Supernatants of L929 and Dalton Lymphoma Cell Lines , J. Cancer Res. 2013 (2013) 1–5. https://doi.org/10.1155/2013/328134.
[61] S. Koch, C.M. Volkmar, V. Kolb-Bachofen, H.G. Korth, M. Kirsch, A.H.C. Horn, H. Sticht, N. Pallua, C. V. Suschek, A new redox-dependent mechanism of MMP-1 activity control comprising reduced low-molecular-weight thiols and oxidizing radicals, J. Mol. Med. 87 (2009) 261–272. https://doi.org/10.1007/s00109-008-0420-5.
[62] Z. Zhang, S.M. Hamilton, C. Stewart, A. Strother, R.W. Teel, Inhibition of liver microsomal cytochrome p450 activity and metabolism of the tobacco-specific nitrosamine NNK by capsaicin and ellagic acid, Anticancer Res. 13 (1993) 2341–2346. https://europepmc.org/article/med/8297156 (accessed January 30, 2021).
[63] A. Constantinou, R. Mehta, C. Runyan, R. Moon, G.D. Stoner, K. Rao, The Dietary Anticancer Agent Ellagic Acid is a Potent Inhibitor of DNA Topoisomerases in Vitro, Nutr. Cancer. 23 (1995) 121–130. https://doi.org/10.1080/01635589509514368.